A Comprehensive Analysis of Clinical Trials in the COVID-19 Pandemic Era
<i>Background and objective:</i> Despite medical advances, we are facing the unprecedented disaster of the coronavirus disease 2019 (COVID-19) pandemic without available treatments and effective vaccines. As the COVID-19 pandemic has approached its culmination, desperate efforts have bee...
| Main Authors: | , , , , , , , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
MDPI AG
2020-06-01
|
| Series: | Medicina |
| Subjects: | |
| Online Access: | https://www.mdpi.com/1010-660X/56/6/315 |
| _version_ | 1797727553340833792 |
|---|---|
| author | Jinhee Lee Han Wul Shin Jun Young Lee Jae Seok Kim Jae Won Yang Keum Hwa Lee Andreas Kronbichler Jae Il Shin |
| author_facet | Jinhee Lee Han Wul Shin Jun Young Lee Jae Seok Kim Jae Won Yang Keum Hwa Lee Andreas Kronbichler Jae Il Shin |
| author_sort | Jinhee Lee |
| collection | DOAJ |
| description | <i>Background and objective:</i> Despite medical advances, we are facing the unprecedented disaster of the coronavirus disease 2019 (COVID-19) pandemic without available treatments and effective vaccines. As the COVID-19 pandemic has approached its culmination, desperate efforts have been made to seek proper treatments and response strategies, and the number of clinical trials has been rapidly increasing. In this time of the pandemic, it is believed that learning lessons from it would be meaningful in preparing for future pandemics. Thus, this study aims at providing a comprehensive landscape of COVID-19 related clinical trials based on the ClinicalTrials.gov database. <i>Materials and methods: </i>Up to 30 March 2020, we identified a total of 147 eligible clinical trials and reviewed the overview of the studies. <i>Results:</i> Until then, the most clinical trials were set up in China. Treatment approaches are the most frequent purpose of the registered studies. Chloroquine, interferon, and antiviral agents such as remdesivir, lopinavir, and ritonavir are agents under investigation in these trials. <i>Conclusions:</i> In this study, we introduced the promising therapeutic options that many researchers and clinicians are interested in, and to address the hidden issues behind clinical trials in this COVID-19 pandemic. |
| first_indexed | 2024-03-12T11:01:25Z |
| format | Article |
| id | doaj.art-5525099111d6484098c6393fca29f8c6 |
| institution | Directory Open Access Journal |
| issn | 1010-660X |
| language | English |
| last_indexed | 2024-03-12T11:01:25Z |
| publishDate | 2020-06-01 |
| publisher | MDPI AG |
| record_format | Article |
| series | Medicina |
| spelling | doaj.art-5525099111d6484098c6393fca29f8c62023-09-02T05:31:31ZengMDPI AGMedicina1010-660X2020-06-015631531510.3390/medicina56060315A Comprehensive Analysis of Clinical Trials in the COVID-19 Pandemic EraJinhee Lee0Han Wul Shin1Jun Young Lee2Jae Seok Kim3Jae Won Yang4Keum Hwa Lee5Andreas Kronbichler6Jae Il Shin7Department of Psychiatry, Yonsei University, Wonju College of Medicine, Wonju Kangwon 26426, KoreaDepartment of Nephrology, Yonsei University, Wonju College of Medicine, Wonju Kangwon 26426, KoreaDepartment of Nephrology, Yonsei University, Wonju College of Medicine, Wonju Kangwon 26426, KoreaDepartment of Nephrology, Yonsei University, Wonju College of Medicine, Wonju Kangwon 26426, KoreaDepartment of Nephrology, Yonsei University, Wonju College of Medicine, Wonju Kangwon 26426, KoreaDepartment of Pediatrics, Yonsei University College of Medicine, Yonsei-ro 50, Seodaemun-gu, C.P.O. Box 8044, Seoul 03722, KoreaDepartment of Internal Medicine IV (Nephrology and Hypertension), Medical University Innsbruck, 6020 Innsbruck, AustriaDepartment of Pediatrics, Yonsei University College of Medicine, Yonsei-ro 50, Seodaemun-gu, C.P.O. Box 8044, Seoul 03722, Korea<i>Background and objective:</i> Despite medical advances, we are facing the unprecedented disaster of the coronavirus disease 2019 (COVID-19) pandemic without available treatments and effective vaccines. As the COVID-19 pandemic has approached its culmination, desperate efforts have been made to seek proper treatments and response strategies, and the number of clinical trials has been rapidly increasing. In this time of the pandemic, it is believed that learning lessons from it would be meaningful in preparing for future pandemics. Thus, this study aims at providing a comprehensive landscape of COVID-19 related clinical trials based on the ClinicalTrials.gov database. <i>Materials and methods: </i>Up to 30 March 2020, we identified a total of 147 eligible clinical trials and reviewed the overview of the studies. <i>Results:</i> Until then, the most clinical trials were set up in China. Treatment approaches are the most frequent purpose of the registered studies. Chloroquine, interferon, and antiviral agents such as remdesivir, lopinavir, and ritonavir are agents under investigation in these trials. <i>Conclusions:</i> In this study, we introduced the promising therapeutic options that many researchers and clinicians are interested in, and to address the hidden issues behind clinical trials in this COVID-19 pandemic.https://www.mdpi.com/1010-660X/56/6/315COVID-19clinical trials |
| spellingShingle | Jinhee Lee Han Wul Shin Jun Young Lee Jae Seok Kim Jae Won Yang Keum Hwa Lee Andreas Kronbichler Jae Il Shin A Comprehensive Analysis of Clinical Trials in the COVID-19 Pandemic Era Medicina COVID-19 clinical trials |
| title | A Comprehensive Analysis of Clinical Trials in the COVID-19 Pandemic Era |
| title_full | A Comprehensive Analysis of Clinical Trials in the COVID-19 Pandemic Era |
| title_fullStr | A Comprehensive Analysis of Clinical Trials in the COVID-19 Pandemic Era |
| title_full_unstemmed | A Comprehensive Analysis of Clinical Trials in the COVID-19 Pandemic Era |
| title_short | A Comprehensive Analysis of Clinical Trials in the COVID-19 Pandemic Era |
| title_sort | comprehensive analysis of clinical trials in the covid 19 pandemic era |
| topic | COVID-19 clinical trials |
| url | https://www.mdpi.com/1010-660X/56/6/315 |
| work_keys_str_mv | AT jinheelee acomprehensiveanalysisofclinicaltrialsinthecovid19pandemicera AT hanwulshin acomprehensiveanalysisofclinicaltrialsinthecovid19pandemicera AT junyounglee acomprehensiveanalysisofclinicaltrialsinthecovid19pandemicera AT jaeseokkim acomprehensiveanalysisofclinicaltrialsinthecovid19pandemicera AT jaewonyang acomprehensiveanalysisofclinicaltrialsinthecovid19pandemicera AT keumhwalee acomprehensiveanalysisofclinicaltrialsinthecovid19pandemicera AT andreaskronbichler acomprehensiveanalysisofclinicaltrialsinthecovid19pandemicera AT jaeilshin acomprehensiveanalysisofclinicaltrialsinthecovid19pandemicera AT jinheelee comprehensiveanalysisofclinicaltrialsinthecovid19pandemicera AT hanwulshin comprehensiveanalysisofclinicaltrialsinthecovid19pandemicera AT junyounglee comprehensiveanalysisofclinicaltrialsinthecovid19pandemicera AT jaeseokkim comprehensiveanalysisofclinicaltrialsinthecovid19pandemicera AT jaewonyang comprehensiveanalysisofclinicaltrialsinthecovid19pandemicera AT keumhwalee comprehensiveanalysisofclinicaltrialsinthecovid19pandemicera AT andreaskronbichler comprehensiveanalysisofclinicaltrialsinthecovid19pandemicera AT jaeilshin comprehensiveanalysisofclinicaltrialsinthecovid19pandemicera |